-
Preclinical and clinical studies with withanolides: Therapeutic effects, molecular signatures and biomarkers
https://braincanada.ca/fr/subventions-financées/preclinical-and-clinical-studies-with-withanolides-therapeutic-effects-molecular-signatures-and-biomarkersOne of the hallmarks of ALS is the presence of abnormal clumps inside motor neurons that contain various substances which include, in the majority of cases, something called TAR DNA–binding protein 43 (TDP-43). Project Overview One of the hallmarks of ALS is the presence of abnormal clumps inside...
-
Preclinical development of a disease modifying small molecule therapy for Alzheimer disease
https://braincanada.ca/fr/subventions-financées/preclinical-development-of-a-disease-modifying-small-molecule-therapy-for-alzheimer-diseaseNo medications exist that can stop or even slow the progression for Alzheimer Disease (AD). Project Overview No medications exist that can stop or even slow the progression for Alzheimer Disease (AD). Several dramatic late stage clinical failures have heightened recognition that novel approaches...
-
Predicting Behavioural Deficits and Creating Biomarkers After Repeated Sub-concussive Injury
https://braincanada.ca/fr/subventions-financées/predicting-behavioural-deficits-and-creating-biomarkers-after-repeated-sub-concussive-injuryConcussions frequently occur worldwide, with a subset of patients experiencing lasting symptoms impacting their quality of life. Project Overview Concussions frequently occur worldwide, with a subset of patients experiencing lasting symptoms impacting their quality of life. Sub-concussive injuries,...
-
Premier traitement regeneratif de la sclerose en plaques
https://braincanada.ca/fr/à-propos-de/nouvelles-mises-à-jour/une-nouvelle-thérapie-prometteuse-pour-la-sclérose-en-plaquesUne équipe de recherche internationale dirigée par la Dre Fang Liu, du Centre de toxicomanie et de santé mentale (CAMH), a reçu près de 800 000 $ US (1 137 868 $ CA) de nouveaux fonds pour faire progresser un traitement prometteur de la sclérose en plaques. Dre Fang Liu, Scientifique principale,...
-
Première plateforme sur la santé mentale des jeunes
https://braincanada.ca/fr/à-propos-de/nouvelles-mises-à-jour/première-plateforme-sur-la-santé-mentale-des-jeunes -
Prenatal serotonin reuptake inhibitor (SRI) antidepressant exposure on brain development, cognition and activity related risk for obesity: A longitudinal study with 10 year olds
https://braincanada.ca/fr/subventions-financées/prenatal-serotonin-reuptake-inhibitor-sri-antidepressant-exposure-on-brain-development-cognition-and-activity-related-risk-for-obesity-a-longitudinal-study-with-10-year-oldsDr. Hutchison‘s training is in lifespan psychology and her research broadly focuses on children’s cognitive and social development. Project Overview Dr. Hutchison‘s training is in lifespan psychology and her research broadly focuses on children’s cognitive and social development. her current...
-
Preventing Language Decline in Dementia
https://braincanada.ca/fr/subventions-financées/preventing-language-decline-in-dementiaPrimary progressive aphasia (PPA) is a form of dementia which impairs the ability to understand spoken and written language but other cognitive skills (including memory) remain intact for several years after its onset. Project Overview Primary progressive aphasia (PPA) is a form of dementia which...
-
Prevention of Alzheimer’s Dementia in High Risk Populations: A Randomized Controlled Trial of a Combination of Cognitive Remediation and Brain Stimulation
https://braincanada.ca/fr/subventions-financées/prevention-of-alzheimer-s-dementia-in-high-risk-populations-a-randomized-controlled-trial-of-a-combination-of-cognitive-remediation-and-brain-stimulationThis project is studying a novel intervention in 250 older persons whose major depression has been successfully treated with an antidepressant medication: a combination of cognitive remediation (CR, consisting of memory and problem solving exercises) plus transcranial Direct Current Stimulation...
-
PRIME-RNA: A platform for in vivo preclinical testing of RNA therapeutics
https://braincanada.ca/fr/subventions-financées/prime-rna-a-platform-for-in-vivo-preclinical-testing-of-rna-therapeuticsRNA medicines—short strands of nucleic acids that can turn genes “up” or “down”—have changed how we treat brain diseases. For example, nusinersen for spinal muscular atrophy and tofersen for ALS are given by spinal injection to reach the brain and spinal cord. These breakthroughs show that RNA drugs...
-
Prioritizing Progressive Supranuclear Palsy: a transformative in vivo model of disease pathogenesis with strong translational value for future drug development
https://braincanada.ca/fr/subventions-financées/prioritizing-progressive-supranuclear-palsy-a-transformative-in-vivo-model-of-disease-pathogenesis-with-strong-translational-value-for-future-drug-developmentProgressive Supranuclear Palsy (PSP) is a deadly disease of the brain with no cure. Project Overview Progressive Supranuclear Palsy (PSP) is a deadly disease of the brain with no cure. By studying the brains of patients who have died scientists have discovered that PSP brains contain toxic deposits...